
Cristina Banfi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8782866/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210. Journal of Biological Chemistry, 2009, 284, 35134-35143.	3.4	248
2	Very Low-Density Lipoprotein Activates Nuclear Factor-κB in Endothelial Cells. Circulation Research, 1999, 84, 1085-1094.	4.5	188
3	Mitochondrial reactive oxygen species: a common pathway for PAR1- and PAR2-mediated tissue factor induction in human endothelial cells. Journal of Thrombosis and Haemostasis, 2009, 7, 206-216.	3.8	141
4	Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. Journal of Hypertension, 2009, 27, 2444-2451.	0.5	113
5	Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1679-1685.	2.4	96
6	Proteome of endothelial cell-derived procoagulant microparticles. Proteomics, 2005, 5, 4443-4455.	2.2	85
7	Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis, 2003, 168, 283-288.	0.8	83
8	Lipoxidation in cardiovascular diseases. Redox Biology, 2019, 23, 101119.	9.0	76
9	Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats. American Journal of Pathology, 2007, 170, 1165-1177.	3.8	70
10	Transcriptional Regulation of Plasminogen Activator Inhibitor Type 1 Gene by Insulin: Insights Into the Signaling Pathway. Diabetes, 2001, 50, 1522-1530.	0.6	69
11	Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiology of Disease, 2006, 22, 445-451.	4.4	66
12	Toward the Standardization of Mitochondrial Proteomics: The Italian Mitochondrial Human Proteome Project Initiative. Journal of Proteome Research, 2017, 16, 4319-4329.	3.7	66
13	Anti-Inflammatory Effects of AT1 Receptor Blockade Provide End-Organ Protection in Stroke-Prone Rats Independently from Blood Pressure Fall. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 989-995.	2.5	59
14	Very Low Density Lipoprotein–Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells. Circulation Research, 1999, 85, 208-217.	4.5	58
15	Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. European Heart Journal, 2005, 26, 481-488.	2.2	56
16	Dkk (Dickkopf) Proteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1330-1342.	2.4	55
17	Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 89-96.	2.4	55
18	Fluvastatin Inhibits Basal and Stimulated Plasminogen Activator Inhibitor 1, but Induces Tissue Type Plasminogen Activator in Cultured Human Endothelial Cells. Thrombosis and Haemostasis, 2000, 84, 59-64.	3.4	53

#	Article	IF	CITATIONS
19	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. British Journal of Haematology, 2004, 127, 97-104.	2.5	53
20	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. Journal of Thrombosis and Haemostasis, 2003, 1, 2322-2329.	3.8	52
21	Lipid Peroxidation in Atherosclerotic Cardiovascular Diseases. Antioxidants and Redox Signaling, 2021, 34, 49-98.	5.4	52
22	Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage. European Journal of Heart Failure, 2008, 10, 244-251.	7.1	49
23	BDNFVal66met polymorphism: a potential bridge between depression and thrombosis. European Heart Journal, 2017, 38, ehv655.	2.2	49
24	P2 receptors in human heart: upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNFα and potential role in myocardial cell death. Journal of Molecular and Cellular Cardiology, 2005, 39, 929-939.	1.9	48
25	Oxidized LDL and Lysophosphatidylcholine Stimulate Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 3025-3032.	2.4	46
26	Proteomic analysis of membrane microdomains derived from both failing and non-failing human hearts. Proteomics, 2006, 6, 1976-1988.	2.2	46
27	Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. Thrombosis and Haemostasis, 2004, 92, 1122-1128.	3.4	42
28	Acute high-altitude exposure reduces lung diffusion: Data from the HIGHCARE Alps project. Respiratory Physiology and Neurobiology, 2013, 188, 223-228.	1.6	42
29	Proteomic analysis of human lowâ€density lipoprotein reveals the presence of prenylcysteine lyase, a hydrogen peroxideâ€generating enzyme. Proteomics, 2009, 9, 1344-1352.	2.2	41
30	Pentoxifylline Prevents Spontaneous Brain Ischemia in Stroke-Prone Rats. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 890-895.	2.5	40
31	Peroxisome Proliferator-Activated Receptor α Agonism Prevents Renal Damage and the Oxidative Stress and Inflammatory Processes Affecting the Brains of Stroke-Prone Rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 324-331.	2.5	39
32	Proteome of platelets in patients with coronary artery disease. Experimental Hematology, 2010, 38, 341-350.	0.4	37
33	Proteomic analysis of endothelial cell secretome: A means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors. Journal of Proteomics, 2013, 78, 346-361.	2.4	37
34	The selected reaction monitoring/multiple reaction monitoring-based mass spectrometry approach for the accurate quantitation of proteins: clinical applications in the cardiovascular diseases. Expert Review of Proteomics, 2014, 11, 771-788.	3.0	36
35	Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics. International Journal of Molecular Sciences, 2020, 21, 4541.	4.1	36
36	Lipid peroxidation derived reactive carbonyl species in free and conjugated forms as an index of lipid peroxidation: limits and perspectives. Redox Biology, 2021, 42, 101899.	9.0	35

#	Article	IF	CITATIONS
37	Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-κB/lκB- and ERK2-dependent mechanisms. Cardiovascular Research, 2002, 55, 406-415.	3.8	34
38	15-Deoxy-Δ12,14-Prostaglandin J2 Inhibits Tissue Factor Expression in Human Macrophages and Endothelial Cells: Evidence for ERK1/2 Signaling Pathway Blockade. Thrombosis and Haemostasis, 2002, 88, 524-532.	3.4	33
39	Terutroban, a Thromboxane/Prostaglandin Endoperoxide Receptor Antagonist, Increases Survival in Stroke-Prone Rats by Preventing Systemic Inflammation and Endothelial Dysfunction: Comparison with Aspirin and Rosuvastatin. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 199-205.	2.5	33
40	Human monocyte-derived macrophages are heterogenous: Proteomic profile of different phenotypes. Journal of Proteomics, 2015, 124, 112-123.	2.4	33
41	Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure. Circulation: Heart Failure, 2009, 2, 175-180.	3.9	32
42	Surfactant-Derived Proteins as Markers of Alveolar Membrane Damage in Heart Failure. PLoS ONE, 2014, 9, e115030.	2.5	32
43	A Preliminary Study on Human Placental Tissue Impaired by Gestational Diabetes: A Comparison of Gel-Based versus Gel-Free Proteomics Approaches. European Journal of Mass Spectrometry, 2016, 22, 71-82.	1.0	31
44	Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics - Clinical Applications, 2010, 4, 71-83.	1.6	30
45	Surfactant protein B and RACE increases in the plasma during cardiopulmonary bypass: a pilot study. European Respiratory Journal, 2011, 37, 841-847.	6.7	30
46	Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. Cardiovascular Research, 2006, 69, 218-226.	3.8	29
47	Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells. Scientific Reports, 2018, 8, 16671.	3.3	29
48	Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes. Free Radical Biology and Medicine, 2019, 144, 245-255.	2.9	28
49	N-Acetyl-Cysteine Regenerates Albumin Cys34 by a Thiol-Disulfide Breaking Mechanism: An Explanation of Its Extracellular Antioxidant Activity. Antioxidants, 2020, 9, 367.	5.1	28
50	On the search for glycated lipoprotein ApoAâ€I in the plasma of diabetic and nephropathic patients. Journal of Mass Spectrometry, 2008, 43, 74-81.	1.6	25
51	A mass spectrometry-based workflow for the proteomic analysis of in vitro cultured cell subsets isolated by means of laser capture microdissection. Analytical and Bioanalytical Chemistry, 2014, 406, 2817-2825.	3.7	25
52	Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. Journal of Lipid Research, 1997, 38, 860-869.	4.2	25
53	Induction of plasminogen activator inhibitor 1 by the PPARα ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. Thrombosis and Haemostasis, 2003, 90, 611-619.	3.4	24
54	Redox Proteomics Identification of Oxidatively Modified Myocardial Proteins in Human Heart Failure: Implications for Protein Function. PLoS ONE, 2012, 7, e35841.	2.5	23

#	Article	IF	CITATIONS
55	Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins. Drug Discovery Today, 2017, 22, 848-869.	6.4	23
56	Coronary artery mechanics induces human saphenous vein remodelling <i>via</i> recruitment of adventitial myofibroblast-like cells mediated by Thrombospondin-1. Theranostics, 2020, 10, 2597-2611.	10.0	23
57	Vascular thrombogenicity induced by progressive LDL oxidation: protection by antioxidants. Thrombosis and Haemostasis, 2003, 89, 544-553.	3.4	22
58	Proteomics of Extracellular Vesicles: Update on Their Composition, Biological Roles and Potential Use as Diagnostic Tools in Atherosclerotic Cardiovascular Diseases. Diagnostics, 2020, 10, 843.	2.6	22
59	Tissue factor induction by protease-activated receptor 1 requires intact caveolin-enriched membrane microdomains in human endothelial cells. Journal of Thrombosis and Haemostasis, 2007, 5, 2437-2444.	3.8	21
60	Cardiomyocyte death induced by ischaemic/hypoxic stress is differentially affected by distinct purinergic P2 receptors. Journal of Cellular and Molecular Medicine, 2012, 16, 1074-1084.	3.6	21
61	Surfactant protein B: From biochemistry to its potential role as diagnostic and prognostic marker in heart failure. International Journal of Cardiology, 2016, 221, 456-462.	1.7	21
62	Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. Journal of Proteomics, 2018, 173, 62-76.	2.4	21
63	Sex-dependent differences in the secretome of human endothelial cells. Biology of Sex Differences, 2021, 12, 7.	4.1	21
64	Digital PCR for high sensitivity viral detection in false-negative SARS-CoV-2 patients. Scientific Reports, 2021, 11, 4310.	3.3	21
65	Apolipoprotein A-II modulates HDL remodeling in plasma. Lipids and Lipid Metabolism, 1992, 1124, 195-198.	2.6	20
66	<i>Nonenzymatically Glycated Lipoprotein ApoAâ€I in Plasma of Diabetic and Nephropathic Patients</i> . Annals of the New York Academy of Sciences, 2008, 1126, 295-299.	3.8	19
67	Novel insights about albumin in cardiovascular diseases: Focus on heart failure. Mass Spectrometry Reviews, 2023, 42, 1113-1128.	5.4	19
68	Aortic valve cell seeding into decellularized animal pericardium by perfusion-assisted bioreactor. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1481-1493.	2.7	18
69	Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. Journal of Lipid Research, 1997, 38, 860-9.	4.2	18
70	Proteomic Analysis of Plasma from Patients Undergoing Coronary Artery Bypass Grafting Reveals a Protease/Antiprotease Imbalance in Favor of the Serpin α1-Antichymotrypsin. Journal of Proteome Research, 2010, 9, 2347-2357.	3.7	17
71	The Effects of Anesthesia, Muscle Paralysis, and Ventilation on the Lung Evaluated by Lung Diffusion for Carbon Monoxide and Pulmonary Surfactant Protein B. Anesthesia and Analgesia, 2015, 120, 373-380.	2.2	17
72	S-Thiolation Targets Albumin in Heart Failure. Antioxidants, 2020, 9, 763.	5.1	17

#	Article	IF	CITATIONS
73	Silencing of FAD synthase gene in Caenorhabditis elegans upsets protein homeostasis and impacts on complex behavioral patterns. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 521-531.	2.4	16
74	Statins prevent tissue factor induction by proteaseâ€activated receptorsÂ1 and 2 in human umbilical vein endothelial cells inÂvitro. Journal of Thrombosis and Haemostasis, 2011, 9, 1608-1619.	3.8	15
75	Association Between Haptoglobin Phenotype and Microvascular Obstruction in Patients With STEMI. JACC: Cardiovascular Imaging, 2019, 12, 1007-1017.	5.3	15
76	Plasma immature form of surfactant protein type B correlates with prognosis in patients with chronic heart failure. A pilot single-center prospective study. International Journal of Cardiology, 2015, 201, 394-399.	1.7	14
77	Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thrombosis and Haemostasis, 2000, 84, 59-64.	3.4	14
78	Prenylcysteine oxidase 1, an emerging player in atherosclerosis. Communications Biology, 2021, 4, 1109.	4.4	13
79	Kinetics of plasma SPB and RAGE during mechanical ventilation in patients undergoing major vascular surgery. Respiratory Physiology and Neurobiology, 2011, 178, 256-260.	1.6	12
80	Surfactant proteins changes after acute hemodynamic improvement in patients with advanced chronic heart failure treated with Levosimendan. Respiratory Physiology and Neurobiology, 2018, 252-253, 47-51.	1.6	12
81	Acrylate-based materials for heart valve scaffold engineering. Biomaterials Science, 2018, 6, 154-167.	5.4	12
82	Is the placental proteome impaired in wellâ€controlled gestational diabetes?. Journal of Mass Spectrometry, 2019, 54, 359-365.	1.6	12
83	Oxidized LDLs influence thrombotic response and cyclooxygenase 2. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 67, 169-173.	2.2	10
84	Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. Vascular Pharmacology, 2015, 67-69, 38-47.	2.1	10
85	Post-translational quantitation by SRM/MRM: applications in cardiology. Expert Review of Proteomics, 2018, 15, 477-502.	3.0	10
86	Proteomic analysis of atherosclerotic plaque. Biomedicine and Pharmacotherapy, 2010, 64, 369-372.	5.6	9
87	Reprint of: Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. Journal of Proteomics, 2018, 178, 57-72.	2.4	9
88	Immature surfactant protein-B impairs the antioxidant capacity of HDL. International Journal of Cardiology, 2019, 285, 53-58.	1.7	9
89	Culture Into Perfusion-Assisted Bioreactor Promotes Valve-Like Tissue Maturation of Recellularized Pericardial Membrane. Frontiers in Cardiovascular Medicine, 2020, 7, 80.	2.4	9
90	Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure. International Journal of Molecular Sciences, 2021, 22, 838.	4.1	9

#	Article	IF	CITATIONS
91	Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis. Respiratory Medicine, 2013, 107, 1617-1624.	2.9	8
92	Serum Proteome in a Sporadic Amyotrophic Lateral Sclerosis Geographical Cluster. Proteomics - Clinical Applications, 2017, 11, 1700043.	1.6	8
93	N-Acetylcysteine Inhibits Platelet Function through the Regeneration of the Non-Oxidative Form of Albumin. Antioxidants, 2022, 11, 445.	5.1	8
94	Altered iron homeostasis in an animal model of hypertensive nephropathy. Journal of Hypertension, 2013, 31, 2259-2269.	0.5	7
95	Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential. Expert Review of Proteomics, 2017, 14, 515-528.	3.0	7
96	D-dimer is associated with arterial and venous coronary artery bypass graft occlusion. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 200-207.e3.	0.8	7
97	Analysis of rosuvatatin by imaging mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 3483-3487.	1.5	6
98	Matrix metalloproteinase and heart failure: is it time to move from research to clinical laboratories?. European Heart Journal, 2007, 28, 659-660.	2.2	6
99	A proteomic approach to identify novel disease biomarkers in LCAT deficiency. Journal of Proteomics, 2019, 198, 113-118.	2.4	6
100	Prenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis. International Journal of Molecular Sciences, 2022, 23, 2831.	4.1	6
101	Proteomics of tissue factor silencing in cardiomyocytic cells reveals a new role for this coagulation factor in splicing machinery control. Journal of Proteomics, 2015, 119, 75-89.	2.4	5
102	Data for proteomic analysis of Human monocyte-derived macrophages. Data in Brief, 2015, 4, 177-179.	1.0	5
103	The application of gene silencing in proteomics: from laboratory to clinic. Expert Review of Proteomics, 2018, 15, 717-732.	3.0	5
104	Cyclooxygenase-2 Glycosylation Is Affected by Peroxynitrite in Endothelial Cells: Impact on Enzyme Activity and Degradation. Antioxidants, 2021, 10, 496.	5.1	5
105	In-Depth AGE and ALE Profiling of Human Albumin in Heart Failure: Ex Vivo Studies. Antioxidants, 2021, 10, 358.	5.1	4
106	Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy. International Journal of Molecular Sciences, 2021, 22, 8954.	4.1	4
107	Vascular thrombogenicity induced by progressive LDL oxidation: protection by antioxidants. Thrombosis and Haemostasis, 2003, 89, 544-53.	3.4	4
108	Plasminogen activator inhibitor type 1 secretion by HepG2 cells. Blood Coagulation and Fibrinolysis, 1996, 7, 503.	1.0	3

#	Article	IF	CITATIONS
109	S 35171 exerts protective effects in spontaneously hypertensive stroke-prone rats by preserving mitochondrial function. European Journal of Pharmacology, 2009, 604, 117-124.	3.5	3
110	Normal human mitral valve proteome: A preliminary investigation by gelâ€based and gelâ€free proteomic approaches. Electrophoresis, 2016, 37, 2633-2643.	2.4	3
111	Immature Circulating SP-B, Bound to HDL, Represents an Early Sign of Smoke-Induced Pathophysiological Alterations. Biomolecules, 2021, 11, 551.	4.0	3
112	Proteomic studies on apoB ontaining lipoprotein in cardiovascular research: A comprehensive review. Mass Spectrometry Reviews, 2023, 42, 1397-1423.	5.4	3
113	Diving and pulmonary physiology: Surfactant binding protein, lung fluid and cardiopulmonary test changes in professional divers. Respiratory Physiology and Neurobiology, 2017, 243, 27-31.	1.6	2
114	Data for proteomic analysis of murine cardiomyocytic HL-1 cells treated with siRNA against tissue factor. Data in Brief, 2015, 3, 117-119.	1.0	1
115	Oxidative Stress and Arginine/Nitric Oxide Pathway in Red Blood Cells Derived from Patients with Prediabetes. Biomedicines, 2022, 10, 1407.	3.2	1
116	Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve. Journal of Visualized Experiments, 2017, , .	0.3	0
117	Chronic Kidney Disease in Acute Myocardial Infarction: Clinical Relevance and Novel Potential Fields of Investigation. Contributions To Statistics, 2013, , 123-136.	0.2	Ο
118	An Optimized MRM-Based Workflow of the l-Arginine/Nitric Oxide Pathway Metabolites Revealed Disease- and Sex-Related Differences in the Cardiovascular Field. International Journal of Molecular Sciences, 2022, 23, 1136.	4.1	0
119	Mercaptoalbumin Is Associated with Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting. Antioxidants, 2022, 11, 702.	5.1	Ο